INS and metabolic dysfunction-associated steatotic liver disease: In contrast, adiponectin—typically reduced in central obesity and MASLD—is considered metabolically protective (95), which enhances insulin sensitivity and exerts anti-inflammatory effects through activation of AMPK and PPAR-α signaling pathways in hepatocytes, reducing steatosis and hepatic inflammation (101).